Summary

CVS Caremark will add Eli Lilly’s oral obesity medicine Foundayo to its formularies on June 1, 2026. Zepbound returns as a preferred option from October 1. Both changes reverse over a year of exclusive preferred status for Novo Nordisk’s Wegovy at CVS. As a result, both companies now hold preferred positions at all three major US pharmacy benefit managers.

Access Impact

Formulary position drove this outcome. Not efficacy. Not clinical novelty.

The CVS decision makes visible how payer placement functions as an independent access determinant — one that operates entirely separately from clinical performance. During CVS’s period of Wegovy exclusivity, Foundayo launched at roughly 30% of oral Wegovy’s prescribing trajectory, according to analyst estimates through week six. Formulary tier appears to have been the primary driver of that gap. Both products compete in the same indication with broadly similar clinical evidence. Consequently, the prescribing divergence was a payer-access outcome — not a clinical one. CVS’s decision to restore parity likely reflects renegotiated pricing terms, not new clinical data.

Care Pathway Integration

Where a medicine sits in a formulary determines who can practically access it. That is the core of Care Pathway Integration as a market-access domain.

In the US, PBM decisions function similarly to reimbursement conditions in other health systems. Specifically, they define the addressable patient population at the point of prescription. Notably, Lilly held preferred status at two other major PBMs throughout the CVS exclusion period. Even so, partial payer access translated directly to partial commercial access. The addition of Foundayo and Zepbound to CVS formularies now opens that patient pool at scale.

Cost-Effectiveness

List price is no longer enough.

Both Lilly and Novo are actively cutting prices for Medicare patients and offering self-pay alternatives. This signals a structural shift in GLP-1 formulary negotiations. Instead of anchoring on clinical novelty, inclusion is increasingly conditional on pricing concessions, rebate structures, and demonstrated real-world value. The restoration of Lilly’s preferred status therefore likely reflects a pricing adjustment — not a clinical one.

Budget Impact and Resources

Adding two preferred-tier GLP-1 medicines to CVS formularies increases cost exposure for employers and health plans. Both Zepbound and Foundayo are high-cost treatments with large potential patient populations. Moreover, granting preferred status to competing products in the same indication simultaneously expands access and raises budget sensitivity. Wider access. Higher cost. Both at once. This is a structural feature of competitive reimbursement markets — and it will remain a key variable in how payers manage the GLP-1 category.

Risk Signal

Two products. Comparable clinical profiles. Different commercial access positions for over a year.

The determining variable was not efficacy — it was formulary placement. For portfolio decision-makers and investors, this outcome illustrates a direct instance of a core principle: clinical success does not determine commercial access. The risk was structural and payer-facing. Furthermore, it was visible before launch. The question is whether this market access risk was assessed and weighted in the portfolio decision — or whether the clinical data was treated as a sufficient proxy for commercial success.

#MarketAccess #HTA #MARArating #GLP1

Explore tirzepatide (Zepbound/Foundayo) independent assessment: https://mararating.com/report/tirzepatide-for-managing-overweight-and-obesity-as-of-september-2025/

Explore semaglutide (Wegovy) independent assessment: https://mararating.com/report/semaglutide-for-managing-overweight-and-obesity-as-of-september-2023-market-access-risk-assessment/